Additional Results from the HELIOS-B Phase 3 study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Presented at the Heart Failure Society of America Annual Scientific Meeting 2024

29 Sep, 2024 Additional Results from the HELIOS-B Phase 3 study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Presented at the Heart Failure Society of America Annual Scientific Meeting 2024

Additional results from the HELIOS-B Phase 3 study of vutrisiran, an RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America Annual Scientific Meeting 2024.

Jering, et al. “Effects of Vutrisiran on Echocardiographic Cardiac Structure and Function: The HELIOS-B Trial”

Maurer, et al. “Exploratory Biomarker Analyses from HELIOS-B, a Phase 3 Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy”